HY-121495-50mg
|
MedChemexpress LLC
|
BKI-1369 [CAS 1951431-22-3]
|
|
COVID-19-immunoregulation
|
|
HY-12887-10mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
HY-12887-25mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
HY-12887-5mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
HY-12887-50mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
HY-13213-10mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
HY-13213-100mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
HY-13213-5mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
HY-13213-50mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
HY-13402-10mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
HY-13402-100mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
HY-13402-25mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
HY-13402-5mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
HY-13402-50mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
HY-13402A-10mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
HY-13402A-100mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
HY-13402A-25mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
HY-13402A-5mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
HY-13402A-50mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
HY-135976-10mg
|
MedChemexpress LLC
|
P2X3 antagonist 34 [CAS 2417288-67-4]
|
|
COVID-19-immunoregulation
|
|
HY-135976-100mg
|
MedChemexpress LLC
|
P2X3 antagonist 34 [CAS 2417288-67-4]
|
|
COVID-19-immunoregulation
|
|
HY-135976-5mg
|
MedChemexpress LLC
|
P2X3 antagonist 34 [CAS 2417288-67-4]
|
|
COVID-19-immunoregulation
|
|
HY-135976-50mg
|
MedChemexpress LLC
|
P2X3 antagonist 34 [CAS 2417288-67-4]
|
|
COVID-19-immunoregulation
|
|
HY-150270A-10mg
|
MedChemexpress LLC
|
NP-1815-PX (sodium) [CAS 1239578-80-3]
|
|
COVID-19-immunoregulation
|
|
HY-150270A-100mg
|
MedChemexpress LLC
|
NP-1815-PX (sodium) [CAS 1239578-80-3]
|
|
COVID-19-immunoregulation
|
|